Back Bay Life Science Report

10 Episodes
Subscribe

By: Jonathan P. Gertler and Peter Bak

Back Bay Life Science Advisors brings you expert insights from our advisors and investment bankers in the world of BioPharma & MedTech. On this podcast, you’ll hear from our experts in life science development, commercialization, and investment banking, scientific investigators, biotech and medtech executives, physicians, and strategists who excel at guiding global life sciences companies and their investors through complex decisions. Join us for insights generated from in-depth scientific, strategic, and financial analysis at the intersection of science and business.

Vaccine Developments 2024: A Podcast Discussion on Latest Vaccine Technology and Ongoing Clinical Developments
#25
03/18/2024

Guests: Pete Bak and Christian Thienel

 

Length: 37 minutes

 

With the advent of COVID-19 in 2020 and 2021, we saw a tremendous amount of interest in not only COVID vaccines, but other companies riding the tailwind and developing vaccine therapies that span across viral illness, maternal infections and bacterial infections.

 

In this episode resident immunologist Dr. Pete Bak and Christian Thienel discuss vaccine technology, up-and-coming areas of interest, such as RSV, and the vaccines currently in late-stage clinical development.

 

Topics in this podcast include:

 

Vac...


Trends and Investment Activity in Radiopharmaceuticals and Psychedelics
#24
02/14/2024

A Podcast Discussion on the Trends and Investment Activity in Radiopharmaceuticals and Psychedelics

Guests: Pete Bak and Christian Thienel
Length: 25 minutes

Here at Back Bay we’ve seen a number of notable trends in the radiopharmaceutical and psychedelic spaces playing out over the past couple of years. Increasingly, investors have been asking our opinions and perspectives on these topics.

Our team has written these whitepapers to address industry interest:

The Radiopharmaceutical Renaissance: Radiating Hope in Medicine
Vision of Commercial Success: Investment and Partnering Landscape for Psychedelics

In th...


Vertex’s Exa-cel to Biogen and Sage’s Zurzuvae: Notable Product Approvals of 2023
#23
01/03/2024

As we move into 2024, Back Bay’s strategic advisors summarize key product approvals from three classes and indications over this past year, including the December CRISPR and Vertex approval of Exa-cel, Biogen and Sage’s August approval of an oral treatment for women with postpartum depression and Genmab and Roche’s May approval in oncology.  

 

In this episode:  

CRISPR and Vertex’s approval of Exa-cel, the first CRISPR-based genetic medicine approved by the FDA in the US The major depressive disorder vs. postpartum depression for Biogen/Sage GenMab and Roche approvals AbbVie acquisition of Cerevel Therap...


Monthly Roundup of News from Healthcare Development
#22
11/07/2023

In our latest podcast, Back Bay Life Science Advisors focused on the chronic and rare disease development of kidney disease. Recently, there have been some changes in treatment, some recent commercial launches and certainly some interest from pharma consolidators, as M&A activity picks up in this area.

 

In this next installment of The Life Science Report, Dr. Pete Bak and Christian Thienel of Back Bay Life Science Advisors talk about kidney disease and the various aspects of the renal disease landscape.

 

Topics in this podcast include:

The links between ca...


The Current and Future Landscape of Healthcare IPO Markets
#21
10/27/2023

with the DNB//Back Bay Partnership for Healthcare

In the current markets, Healthcare continues to rally as the second-largest industry behind technology in the stock market, and in the US markets there’s been roughly $2.5B raised from an IPO standpoint YTD. In Europe, the markets have been more challenging, with IPOs for five companies going public this year, including Schott Pharma, Germany’s largest IPO earlier this year.

In the first podcast episode with the DNB//Back Bay Partnership for Healthcare, Jonathan Gertler, Back Bay CEO and Managing Partner is joined by Jim Cirenza, Head...


The Heart of the Matter: Behind the Renewed Interest in Cardiovascular Disease
#20
10/12/2023

A conversation on the rising trends in the cardiology space

Cardiology has historically been a cornerstone of large pharmaceutical portfolios. The late 2000s and 2010s saw many pharmaceutical companies and investors abandon or severely deprioritize cardiology research and development in favor of oncology, immunology, and neurology.

During this episode of The Life Science Report, Dr. Pete Bak and Christian Thienel of Back Bay Life Science Advisors discuss the major players in the industry and novel approaches to future cardiology applications.


Episode topics include: 

Why pharma’s interest in specialty-like approaches has shi...


The Transactional Landscape Of ADCs: The Powerhouse of Antibody Drug Conjugates
#19
08/29/2023

In this episode, Dr. Peter Bak is joined by Trent Gordon and Dr. Mavra Nasir as they discuss their Bioprocess Online article published earlier this year, “The Transactional Landscape of ADCs: A Payday for Payloads.” This conversation explores the dynamics and data within the emerging ADC field, including:

Background information on the class of therapeutics known as ADCs, which have been on the market since 2000The number of headlines around ADCs lately, especially the standing ovation the data from Enhertu received at ASCO in 2022, making waves in breast cancer treatmentDeal structures and the BD side of ADCs, and thei...


Investing in Health Tech & Digital Medicine: Expert Talk with Mikaela Odlander & Edward Kliphuis
#18
04/14/2023

The world of health tech has changed dramatically since decades ago when physicians had to endure 11 keystrokes to prescribe a single aspirin. These days, AI-based radiology and AI-based pathology are transforming patient lives through machine learning and data analytics, in some cases offering early disease warning systems and improving quality of care while reducing healthcare costs.  

 

In this episode of Back Bay’s industry podcast, the Life Science Report, Jonathan Gertler speaks with Mikaela Odlander, Director of Digital Therapeutics at Orexo, and Edward Kliphuis, Partner at Sofinnova Partners, about the opportunities and challenges ahead in the...


Contingencies for Biopharma, Medtech Deal Planning in a Down Market
#17
02/09/2023

For biopharma and medtech companies developing new treatments, capital for advancement and growth is invariably dependent on strategic preparation, differentiation, and persistence. Good preparation can mean funding or famine in a retracted market—and ultimately can impact the trajectory of a company and whether treatment reaches people in the clinical setting.

 

In a down market, there are creative and thoughtful approaches companies can take to stand out as capital becomes more closely guarded and the competition becomes fierce. 

 

In this episode of Back Bay’s industry podcast, the Life Science Report, Jonatha...


Gene Editing to Cross-Species Transplantation: The Most Compelling Healthcare Stories of 2022
#16
01/24/2023

In our first podcast episode of 2023, Back Bay’s strategic advisors summarize some of the most compelling healthcare development stories from 2022. From CRISPR and gene editing advancement to cross-species organ transplantation and the latest in the evolving regulatory and reimbursement landscape,  these stories captivated us and continue to herald progress in health and human care. 

Podcast experts include Brendan Wang, Christian Thienel and Peter Bak, with special thanks to Micheka Fenelon.